Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: Sadif Analytics Prime
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc reaffirms FY 2013 revenue guidance; gives FY 2014 guidance in line with analysts' estimates - Conference Call

Tuesday, 7 Jan 2014 08:00am EST 

Valeant Pharmaceuticals International Inc:Says for FY 2013 it reiterates its previous guidance and expect to be in the revenue range of $5.7 billion to $5.9 billion.Says FY 2014 revenue to be in the range of $8.2 billion to $8.6 billion.Says FY 2014 cash EPS guidance in the range of $8.25 to $8.75 per share.FY 2013 revenue of $5.8 billion - Thomson Reuters I/B/E/S Estimates.FY 2014 revenue of $8.3 billion and EPS of $8.70 - Thomson Reuters I/B/E/S Estimates.